Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Virpax Pharmaceuticals ( (VRPX) ) has shared an announcement.
On February 5, 2025, Virpax Pharmaceuticals appointed Charn Deol as an independent director following the resignation of Jaydriane Panis. Mr. Deol, with over 35 years of public company management experience, will also serve as Chair of the Audit Committee and join the Compensation and Nominating and Corporate Governance Committees. His appointment is expected to enhance Virpax’s strategic oversight, leveraging his extensive experience in guiding Canadian companies through public market regulatory processes.
More about Virpax Pharmaceuticals
YTD Price Performance: -21.35%
Average Trading Volume: 3,938,994
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $5.35M
Learn more about VRPX stock on TipRanks’ Stock Analysis page.